Prima BioMed Cash on Hand 2010-2021 | IMMP
Prima BioMed cash on hand from 2010 to 2021. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Prima BioMed Annual Cash on Hand
(Millions of US $) |
| 2021 |
$45 |
| 2020 |
$18 |
| 2019 |
$12 |
| 2018 |
$18 |
| 2017 |
$9 |
| 2016 |
$15 |
| 2015 |
$6 |
| 2014 |
$19 |
| 2013 |
$31 |
| 2012 |
$39 |
| 2011 |
$55 |
| 2010 |
$14 |
| 2009 |
$1 |
Prima BioMed Quarterly Cash on Hand
(Millions of US $) |
| 2017-03-31 |
$11 |
| 2016-12-31 |
$12 |
| 2016-06-30 |
$15 |
| 2015-12-31 |
$20 |
| 2015-06-30 |
$6 |
| 2014-12-31 |
$5 |
| 2014-06-30 |
$19 |
| 2013-12-31 |
$27 |
| 2013-06-30 |
$31 |
| 2012-12-31 |
$29 |
| 2012-06-30 |
$39 |
| 2011-06-30 |
$55 |
| 2010-06-30 |
$14 |
| 2009-06-30 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.174B |
$0.003B |
|
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
|
